MECOM
MECOM (Histone-lysine N-methyltransferase MECOM) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Prostate cancer, Endometrial cancer and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Functions as a transcriptional regulator binding to DNA sequences in the promoter region of target genes and regulating positively or negatively their expression. Oncogene which plays a role in development, cell proliferation and differentiation. May also play a role in apoptosis through regulation of the JNK and TGF-beta signalling. Involved in haematopoiesis. Displays histone methyltransferase activity and monomethylates 'Lys-9' of histone H3 (H3K9me1). Probably catalyses the monomethylation of free histone H3 in the cytoplasm which is then transported to the nucleus and incorporated into nucleosomes where SUV39H methyltransferases use it as a substrate to catalyse histone H3 'Lys-9' trimethylation. Location: Nucleus; Nucleus speckle; Cytoplasm (UniProt). Locus 3q26.2 (HGNC).
- Breast cancer: Open Targets association 0.59 with breast cancer (MONDO_0007254); IntOGen driver in 1 cohort (BRCA)
- Prostate cancer: Open Targets association 0.54 with prostate cancer (MONDO_0008315); IntOGen driver in 1 cohort (PRAD)
- Endometrial cancer: IntOGen driver in 1 cohort (UCEC)
- Skin cancer: Open Targets association 0.57 with skin cancer (MONDO_0002898)
- Lung cancer: Open Targets association 0.54 with lung cancer (MONDO_0008903)
- Ovarian cancer: Open Targets association 0.51 with ovarian cancer (MONDO_0008170)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"MECOM" OR ABSTRACT:"MECOM" OR TITLE:"MDS1 and EVI1 complex locus" OR ABSTRACT:"MDS1 and EVI1 complex locus" OR TITLE:"Histone-lysine N-methyltransferase MECOM" OR ABSTRACT:"Histone-lysine N-methyltransferase MECOM" OR TITLE:"MDS1-EVI1" OR ABSTRACT:"MDS1-EVI1" OR TITLE:"PRDM3" OR ABSTRACT:"PRDM3" OR TITLE:"KMT8E" OR ABSTRACT:"KMT8E") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MECOM, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/mecom.json. Licence CC BY-NC 4.0.